CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS:SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Solid Biosciences investors should visit us at https://www.claimsfiler.com/cases/view-solid-biosciences-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company’s delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences’ shares plummeted over 60% to $9.32/share on March 15, 2018.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
